Copaxone Supreme Court Case Could Cut Relitigation Of Patent Claims
Executive Summary
Supreme Court to hear oral arguments in case that could restrict the ability of the Federal Circuit to overturn certain rulings on patent claim terms; Google, Intel and other tech companies back Sandoz.
You may also be interested in...
Teva’s Copaxone Patent Win Delivers Bigger Blow To Sandoz Than Mylan
Sandoz, which has first to file on the generic, may have the most to lose after federal judge finds that Mylan and Sandoz ANDAs for generic Copaxone infringe all the claims in Teva’s patents, the latest of which expires in September 2015. FDA now has more time to review the ANDAs without pressure.
FTC Commissioner Recusal Decisions Should Be Public, US Chamber Of Commerce Says
Chamber files petition to have FTC amend its disqualification rules to have commissioners explain their rejection of recusal requests. FTC is seeking public comments on the petition.
FTC Merger Guidelines Cast ‘Perilous Shadow’ Over Biopharma
BIO objects to guidelines seeking to block mergers that would eliminate a potential entrant in a concentrated market and give greater scrutiny to transactions that are part of a series of company deals. APhA and NCPA call for FTC to consider more factors in PBM mergers.